Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment
Shruti Rao, Robert A. Beckman, Shahla Riazi, et al.
Oncotarget (2016) Vol. 8, Iss. 23, pp. 37923-37934
Open Access | Times Cited: 22

Showing 22 citing articles:

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
Michael J. Pishvaian, R Joseph Bender, David Halverson, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 20, pp. 5018-5027
Open Access | Times Cited: 194
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin A. Weinberg, Joanne Xiu, Michael Lindberg, et al.
Journal of Gastrointestinal Oncology (2019) Vol. 10, Iss. 4, pp. 652-662
Open Access | Times Cited: 151
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer
Michael J. Pishvaian, Rebecca Slack, Wei Jiang, et al.
Cancer (2018) Vol. 124, Iss. 11, pp. 2337-2346
Open Access | Times Cited: 59
Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study
Cinzia Tesauro, Anne Simonsen, Marie B. Andersen, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 44
Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer
Margareta Pernar Kovač, Vanja Tadić, Juran Kralj, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 10
Open Access | Times Cited: 10
Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells
Anke Rauch, Annemarie Carlstedt, Claudia Emmerich, et al.
Oncotarget (2018) Vol. 9, Iss. 45, pp. 27835-27850
Open Access | Times Cited: 24
Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma
Maria‐Magdalena Georgescu, Mohammad Zahidul Islam, Y. Li, et al.
Acta Neuropathologica Communications (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 22
Toxicogenomic and bioinformatics platforms to identify key molecular mechanisms of a curcumin-analogue DM-1 toxicity in melanoma cells
Érica Aparecida de Oliveira, Diógenes S. de Lima, Lucas E. Cardozo, et al.
Pharmacological Research (2017) Vol. 125, pp. 178-187
Closed Access | Times Cited: 20
eGARD: Extracting associations between genomic anomalies and drug responses from text
A. S. M. Ashique Mahmood, Shruti Rao, Peter B. McGarvey, et al.
PLoS ONE (2017) Vol. 12, Iss. 12, pp. e0189663-e0189663
Open Access | Times Cited: 16
Tackling non-muscle invasive bladder cancer in the clinic
Solomon L. Woldu, Öner Şanlı, Yair Lotan
Expert Review of Anticancer Therapy (2017) Vol. 17, Iss. 5, pp. 467-480
Closed Access | Times Cited: 15
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Si Shi, Xianjun Yu
Seminars in Oncology (2018) Vol. 46, Iss. 1, pp. 39-47
Open Access | Times Cited: 13
Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration
Simina M. Boca, Orestis A. Panagiotou, Shruti Rao, et al.
JCO Precision Oncology (2018), Iss. 2, pp. 1-1
Open Access | Times Cited: 10
The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
Frederik van Delft, Hendrik Koffijberg, Valesca P. Retèl, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1120-1120
Open Access | Times Cited: 9
Evidence-Based Network Approach to Recommending Targeted Cancer Therapies
Jayaram Kancherla, Shruti Rao, Krithika Bhuvaneshwar, et al.
JCO Clinical Cancer Informatics (2020), Iss. 4, pp. 71-88
Open Access | Times Cited: 8
Eye-Tracking Study to Enhance Usability of Molecular Diagnostics Reports in Cancer Precision Medicine
Vishakha Sharma, Allan Fong, Robert A. Beckman, et al.
JCO Precision Oncology (2018), Iss. 2, pp. 1-11
Open Access | Times Cited: 8
A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Anteneh Tesfaye, Hongkun Wang, Marion L. Hartley, et al.
Journal of Pancreatic Cancer (2019) Vol. 5, Iss. 1, pp. 12-21
Open Access | Times Cited: 4
A framework for assessing the impact of accelerated approval
A. Lawrence Gould, R. Keith Campbell, John W. Loewy, et al.
PLoS ONE (2022) Vol. 17, Iss. 6, pp. e0265712-e0265712
Open Access | Times Cited: 3
DNA Damage Repair Classifier Defines Distinct Groups in Hepatocellular Carcinoma
Markia A. Smith, Sarah C. Van Alsten, Andrea Walens, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4282-4282
Open Access | Times Cited: 3
eGARD: Extracting associations between genomic anomalies and drug responses from text
A. S. M. Ashique Mahmood, Shruti Rao, Peter B. McGarvey, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2017)
Open Access
Chemotherapy Resistance
Adrienne C. Scheck
Elsevier eBooks (2018), pp. 87-104
Closed Access
An evidence-based network approach to recommending targeted cancer therapies
Jayaram Kancherla, Shruti Rao, Krithika Bhuvaneshwar, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access
A Framework for Assessing the Impact of Accelerated Approval
A. Lawrence Gould, R. Keith Campbell, John W. Loewy, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top